While PD-L1 status is often used to guide immune checkpoint inhibitor therapy, current clinical evidence suggests that PD-1 inhibitors may demonstrate efficacy in renal cell carcinoma irrespective of PD-L1 expression levels. This evidence concerns the gene CD274 and hereditary clear cell renal cell carcinoma.